menu

HDFN: New Understandings of Risk, Diagnosis, and Therapeutic Approaches

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

HDFN: New Understandings of Risk, Diagnosis, and Therapeutic Approaches

close
0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Hemolytic disease of the fetus and newborn (HDFN) is a rare disease that occurs due to the incompatibility between fetal and maternal red cell antigens. HDFN can lead to both short- and long-term consequences, including potentially fatal outcomes. In order to better prevent these associated issues, the timely evaluation, recognition, and treatment of HDFN are critical.

    Listen in as three leading experts, Drs. Lee Shulman, Kenneth Moise, and Christopher Robinson, join together to discuss new epidemiologic evidence, the underlying pathophysiology of HDFN, health equity, and evolving management strategies you can implement to improve your clinical practice.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Lee P. Shulman, MD, FACMG, FACOG
    The Anna Ross Lapham Professor in Obstetrics and Gynecology (Clinical Genetics)
    Feinberg School of Medicine
    Northwestern University
    Chicago, IL
    Consulting Fees: Biogix, Celula, CooperSurgical, Natera, Vermillion/Aspira
    Commercial Interest Speakers Bureau: Bayer, Lupin Pharmaceuticals, Inc., Myriad

    Faculty:
    Kenneth J. Moise Jr, MD
    Professor of Obstetrics and Gynecology
    Department of Women's Health
    Dell Medical School
    Director, Comprehensive Fetal Care Center
    Dell Children's Medical Center
    Austin, TX
    Royalty: UpToDate, Inc.
    Contracted Research: Momenta Pharmaceuticals, Inc.

    Christopher J. Robinson, MD, MSCR, FACOG
    Chief/Chair, Obstetrics & Gynecology
    Director, Maternal Fetal Medicine
    East Cooper Medical Center
    Mt. Pleasant, SC
    Contracted Research: Seqirus
    Consulting Fees: CAS Corp, Progenity 

    Reviewers/Content Planners/Authors:

    • Sean Barrett has nothing to disclose.
    • Estelle Perera has nothing to disclose.
    • Robert Schneider, MSW, has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Explain the epidemiology and pathophysiology underlying fetal/newborn allo- and autoimmune diseases, with a focus on HDFN
    • Identify current diagnostic and treatment regimens for HDFN
  • Target Audience

    This activity is designed to meet the educational needs of obstetrician-gynecologists and maternal-fetal medicine specialists, as well as nurse practitioners and physician assistants.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

    Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.

  • Commercial Support

    This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Hemolytic disease of the fetus and newborn (HDFN) is a rare disease that occurs due to the incompatibility between fetal and maternal red cell antigens. HDFN can lead to both short- and long-term consequences, including potentially fatal outcomes. In order to better prevent these associated issues, the timely evaluation, recognition, and treatment of HDFN are critical.

    Listen in as three leading experts, Drs. Lee Shulman, Kenneth Moise, and Christopher Robinson, join together to discuss new epidemiologic evidence, the underlying pathophysiology of HDFN, health equity, and evolving management strategies you can implement to improve your clinical practice.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Lee P. Shulman, MD, FACMG, FACOG
    The Anna Ross Lapham Professor in Obstetrics and Gynecology (Clinical Genetics)
    Feinberg School of Medicine
    Northwestern University
    Chicago, IL
    Consulting Fees: Biogix, Celula, CooperSurgical, Natera, Vermillion/Aspira
    Commercial Interest Speakers Bureau: Bayer, Lupin Pharmaceuticals, Inc., Myriad

    Faculty:
    Kenneth J. Moise Jr, MD
    Professor of Obstetrics and Gynecology
    Department of Women's Health
    Dell Medical School
    Director, Comprehensive Fetal Care Center
    Dell Children's Medical Center
    Austin, TX
    Royalty: UpToDate, Inc.
    Contracted Research: Momenta Pharmaceuticals, Inc.

    Christopher J. Robinson, MD, MSCR, FACOG
    Chief/Chair, Obstetrics & Gynecology
    Director, Maternal Fetal Medicine
    East Cooper Medical Center
    Mt. Pleasant, SC
    Contracted Research: Seqirus
    Consulting Fees: CAS Corp, Progenity 

    Reviewers/Content Planners/Authors:

    • Sean Barrett has nothing to disclose.
    • Estelle Perera has nothing to disclose.
    • Robert Schneider, MSW, has nothing to disclose.
    • Anna Trentini has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Explain the epidemiology and pathophysiology underlying fetal/newborn allo- and autoimmune diseases, with a focus on HDFN
    • Identify current diagnostic and treatment regimens for HDFN
  • Target Audience

    This activity is designed to meet the educational needs of obstetrician-gynecologists and maternal-fetal medicine specialists, as well as nurse practitioners and physician assistants.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

    Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.

  • Commercial Support

    This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Programs 9/25/21